Weihprecht H, Lorenz J N, Briggs J P, Schnermann J
Department of Physiology, University of Michigan, Ann Arbor 48104.
Am J Physiol. 1992 Dec;263(6 Pt 2):F1026-33. doi: 10.1152/ajprenal.1992.263.6.F1026.
To examine the vasomotor effects of purinergic agonists, experiments were performed in isolated afferent arterioles of rabbit kidneys dissected together with their glomerulus and perfused with a pressure head of 120 cmH2O. Changes in vascular diameter were taken as measure of changes in vasomotor tone. Adenosine caused a dose-dependent and persistent decrease in vascular diameter along the entire afferent arteriole with significant changes being detectable at 10(-8) M. Constrictor effects were more pronounced in the glomerular entrance segment of the arteriole where adenosine caused a progressive diameter reduction with maximum contraction at 10(-4) M. Similar monophasic diameter reductions of the distal afferent arteriole were seen with increasing bath concentrations of 2-chloroadenosine (2-ClAdo), cyclohexyladenosine (CHA), and 5'-(N-ethylcarboxamido)adenosine (NECA). Concentrations to achieve half-maximum responses were 92.5 nM for 2-ClAdo, 39 nM for CHA, and 107 nM for NECA. The A2-receptor agonist N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine had no effect on vessel diameter. Increasing bath concentrations of ATP caused significant diameter reductions in both the proximal and distal parts of the afferent arterioles. Addition of the A1-receptor blocker, 8-cyclopentyl-1,3-dipropylxanthine, eliminated the effect of ATP in the proximal region of the arteriole, but a significant diameter reduction was still seen in the glomerular entrance segment. The ATP analogue, beta gamma-methylene-ATP, caused a significant diameter reduction in this segment. These results are consistent with an essentially exclusive presence of A1 receptors in the glomerular entrance segment of the afferent arteriole, whereas in more proximal regions A2 receptors appear to also be expressed in low density. These studies also provide functional evidence for the presence of P2x receptors in renal afferent arterioles.
为研究嘌呤能激动剂的血管运动效应,实验在分离的兔肾传入小动脉上进行,这些小动脉与其肾小球一起被分离,并以120 cmH₂O的压力头进行灌注。血管直径的变化被用作血管运动张力变化的指标。腺苷导致整个传入小动脉的血管直径呈剂量依赖性且持续减小,在10⁻⁸ M时可检测到显著变化。收缩效应在小动脉的肾小球入口段更为明显,在此处腺苷导致直径逐渐减小,在10⁻⁴ M时达到最大收缩。随着浴槽中2 - 氯腺苷(2-ClAdo)、环己基腺苷(CHA)和5'-(N - 乙基甲酰胺基)腺苷(NECA)浓度的增加,在远端传入小动脉也观察到类似的单相直径减小。达到半数最大反应的浓度分别为:2-ClAdo为92.5 nM,CHA为39 nM,NECA为107 nM。A₂受体激动剂N⁶-[2-(3,5 - 二甲氧基苯基)-2-(2 - 甲基苯基)乙基]腺苷对血管直径无影响。浴槽中ATP浓度增加导致传入小动脉近端和远端的直径均显著减小。加入A₁受体阻滞剂8 - 环戊基 - 1,3 - 二丙基黄嘌呤可消除ATP在小动脉近端区域的效应,但在肾小球入口段仍可见显著的直径减小。ATP类似物βγ - 亚甲基 - ATP在此段导致显著的直径减小。这些结果与传入小动脉肾小球入口段基本上仅存在A₁受体一致,而在更靠近近端的区域,A₂受体似乎也以低密度表达。这些研究还为肾传入小动脉中P2x受体的存在提供了功能证据。